Novartis India to Acquire Pfizer's 'Minipress' Trademark for Rs 1,250 Crore

Maharashtra: Novartis India buys Minipress brands from Pfizer for Rs 1250 crore

Following the approval, Novartis India signed an asset purchase agreement and trademark assignment deeds: Reports

Novartis India Expands Portfolio With INR 1,250 Crore Acquisition of Pfizer's Minipress Trademarks

Novartis India has agreed to acquire Pfizer's 'Minipress' and 'Minipres' trademarks in India for INR 1,250 crore. Meanwhile, Pfizer Ltd announced it will discontinue the marketing and sale of Minipress XL following a global manufacturing halt by Pfizer Inc. Minipress XL is prescribed in India primarily for treating hypertension or high blood pressure. Novartis India Expands Portfolio With INR 1,250 Crore Acquisition of Pfizer's Minipress Tradema…

Minipress changes hands: Novartis India buys Pfizer brands for Rs 1,250 crore

Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property, while Pfizer Ltd has stopped selling Minipress XL from September 7.

Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore

Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and benign prostatic hyperplasia, generated ₹228.6 crore in revenue as of July 2026, according to IQVIA data.

Novartis India to acquire Pfizer's ‘Minipress’ trademark for ₹1,250 crore

Novartis India Ltd on Monday announced that its Board of Directors has approved the acquisition of the trademarks 'Minipress' and 'Minipres' from Pfizer Inc. USA and Pfizer Products Inc. USA for a total consideration of approximately Rs 1,250 crore.

Novartis India inks $132M asset purchase deal with Pfizer for Minipress brands (NVS:NYSE)

Novartis India to acquire Pfizer’s Minipress/Minipres trademarks for ₹12.5B; impact on hypertension and BPH treatment in India—read the details now.